RATIONALE: The atypical antipsychotic drug (APD) clozapine (CLZ) has been shown to have a robust discriminative cue in rats, pigeons, and monkeys in two-choice drug discrimination procedures. OBJECTIVES: The present study determined whether a two-choice drug discrimination procedure with CLZ could be established in C57BL/6 mice and whether this procedure could distinguish between atypical and typical APDs. METHODS: C57BL/6 male mice were trained to discriminate 2.5 mg/kg CLZ from vehicle in a two-lever drug discrimination procedure. RESULTS: Generalization testing with CLZ produced full substitution at the 2.5- and 5.0-mg/kg doses with an ED50 of 1.14 mg/kg. The atypical APDs olanzapine (ED50=0.24 mg/kg), risperidone (ED50=0.072 mg/kg), and ziprasidone (ED50=0.33 mg/kg) fully substituted for CLZ's discriminative cue, while the typical APD haloperidol failed to substitute for CLZ. Generalization testing with selective ligands showed that the serotonin (5-HT)2A/2B/2C antagonist ritanserin fully substituted for CLZ (ED50=2.08 mg/kg) and that the 5-HT receptor agonist quipazine significantly attenuated CLZ's discriminative cue without disrupting response rates. The muscarinic receptor antagonist scopolamine, the dopamine agonist amphetamine, and the 5-HT agonist quipazine failed to substitute for CLZ. CONCLUSIONS: These results demonstrated that antagonism of 5-HT receptors plays an important role in mediating the discriminative stimulus properties of the atypical APD CLZ in C57BL/6 mice. The atypical APDs olanzapine, risperidone, and ziprasidone fully substituted for CLZ, while the typical APD haloperidol did not. These results suggest that CLZ drug discrimination in C57BL/6 mice may be an effective preclinical behavioral assay for screening atypical from typical antipsychotic drugs.
RATIONALE: The atypical antipsychotic drug (APD) clozapine (CLZ) has been shown to have a robust discriminative cue in rats, pigeons, and monkeys in two-choice drug discrimination procedures. OBJECTIVES: The present study determined whether a two-choice drug discrimination procedure with CLZ could be established in C57BL/6 mice and whether this procedure could distinguish between atypical and typical APDs. METHODS: C57BL/6 male mice were trained to discriminate 2.5 mg/kg CLZ from vehicle in a two-lever drug discrimination procedure. RESULTS: Generalization testing with CLZ produced full substitution at the 2.5- and 5.0-mg/kg doses with an ED50 of 1.14 mg/kg. The atypical APDs olanzapine (ED50=0.24 mg/kg), risperidone (ED50=0.072 mg/kg), and ziprasidone (ED50=0.33 mg/kg) fully substituted for CLZ's discriminative cue, while the typical APD haloperidol failed to substitute for CLZ. Generalization testing with selective ligands showed that the serotonin (5-HT)2A/2B/2C antagonist ritanserin fully substituted for CLZ (ED50=2.08 mg/kg) and that the 5-HT receptor agonist quipazine significantly attenuated CLZ's discriminative cue without disrupting response rates. The muscarinic receptor antagonist scopolamine, the dopamine agonist amphetamine, and the 5-HT agonist quipazine failed to substitute for CLZ. CONCLUSIONS: These results demonstrated that antagonism of 5-HT receptors plays an important role in mediating the discriminative stimulus properties of the atypical APD CLZ in C57BL/6 mice. The atypical APDs olanzapine, risperidone, and ziprasidone fully substituted for CLZ, while the typical APD haloperidol did not. These results suggest that CLZ drug discrimination in C57BL/6 mice may be an effective preclinical behavioral assay for screening atypical from typical antipsychotic drugs.
Authors: A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen Journal: Psychopharmacology (Berl) Date: 1996-03 Impact factor: 4.530
Authors: J C Winter; A K Kieres; M D Zimmerman; C J Reissig; J R Eckler; T Ullrich; K C Rice; R A Rabin; J B Richards Journal: Pharmacol Biochem Behav Date: 2005-08 Impact factor: 3.533
Authors: Timothy J Donahue; Todd M Hillhouse; Kevin A Webster; Richard Young; Eliseu O De Oliveira; Joseph H Porter Journal: Psychopharmacology (Berl) Date: 2017-09-18 Impact factor: 4.530
Authors: Alison A Williams; Wendy M Ingram; Sarah Levine; Jack Resnik; Christy M Kamel; James R Lish; Diana I Elizalde; Scott A Janowski; Joseph Shoker; Alexey Kozlenkov; Javier González-Maeso; Amelia L Gallitano Journal: Neuropsychopharmacology Date: 2012-06-13 Impact factor: 7.853
Authors: Scott D Philibin; D Matthew Walentiny; Sarah A Vunck; Adam J Prus; Herbert Y Meltzer; Joseph H Porter Journal: Psychopharmacology (Berl) Date: 2008-11-07 Impact factor: 4.530
Authors: Adam J Prus; Alan L Pehrson; Scott D Philibin; Jesse T Wood; Sarah A Vunck; Joseph H Porter Journal: Psychopharmacology (Berl) Date: 2008-08-07 Impact factor: 4.530
Authors: Robert E Vann; Jonathan A Warner; Kristen Bushell; John W Huffman; Billy R Martin; Jenny L Wiley Journal: Eur J Pharmacol Date: 2009-05-23 Impact factor: 4.432
Authors: Martilias S Farrell; John D McCorvy; Xi-Ping Huang; Daniel J Urban; Kate L White; Patrick M Giguere; Allison K Doak; Alison I Bernstein; Kristen A Stout; Su Mi Park; Ramona M Rodriguiz; Bradley W Gray; William S Hyatt; Andrew P Norwood; Kevin A Webster; Brenda M Gannon; Gary W Miller; Joseph H Porter; Brian K Shoichet; William E Fantegrossi; William C Wetsel; Bryan L Roth Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240